9 Meters Biopharma, Inc. (NMTRQ)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.8878 - Volume
7 - Avg. Volume
0 - Market Cap (intraday)
14 - Beta (5Y Monthly) 48.08
- PE Ratio (TTM)
-- - EPS (TTM)
-3.5200 - Earnings Date Apr 29, 2024 - May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
www.9meters.comRelated News
Performance Overview: NMTRQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMTRQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMTRQ
Valuation Measures
Market Cap
1.45k
Enterprise Value
-1.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-111.78%
Return on Equity (ttm)
-375.64%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-46.28M
Diluted EPS (ttm)
-3.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
6.94M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-21.02M